Machine learning for estimation of building energy consumption and performance:a review

Ever growing population and progressive municipal business demands for constructing new buildings are known as the foremost contributor to greenhouse gasses. Therefore, improvement of energy eciency of the building sector has become an essential target to reduce the amount of gas emission as well as fossil fuel consumption. One most eective approach to reducing CO2 emission and energy consumption with regards to new buildings is to consider energy eciency at a very early design stage. On the other hand, ecient energy management and smart refurbishments can enhance energy performance of the existing stock. All these solutions entail accurate energy prediction for optimal decision making. In recent years, articial intelligence (AI) in general and machine learning (ML) techniques in specic terms have been proposed for forecasting of building energy consumption and performance. This paperprovides a substantial review on the four main ML approaches including articial neural network, support vector machine, Gaussian-based regressions and clustering, which have commonly been applied in forecasting and improving building energy performance

Miocardiopatia da Stress

Descrizione delle caratteristiche cliniche dalla miocardiopatia da stress in generale e della sindrome cosiddetta Tako-Tsubo in particolar

First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients.

[ARTICOLO

Mechanical vs. electrical dyssynchrony for CRTselection in patients with HF

Background: Cardiac resynchronization therapy (CRT) is a new approach to treat of refractory heart failure (HF). Electrical dyssynchrony (ED) is used for selection of candidates to CRT. However, mechanical dyssynchrony (MD) may be more appropriate as it evaluates contraction. Aim: To evaluate the relationship between ED and MD in patients potentially candidates to CRT. Methods: One hundred five patients with HF (mean age 65± 20 years, NYHA class III-IV, sinus rhythm, LVEF <35%, optimized medical therapy and complete or incomplete BBB) were studied. The patients were classified in 3 groups based on QRS duration: A= 150 ms. Three indexes of interventricular MD were measured: Qa-Qp by conventional Doppler and QT-QM and QT-QMonset by tissue Doppler imaging. Results: (1) MD was observed in all the 3 groups, with a 40% prevalence in A. (2) This was true for non-ischemic and ischemic HF etiologies. (3) QRS duration correlated weakly with MD indexes. (4) The type of electrical conduction disturbance (LBBB, RBBB) did not to influence the prevalence of MD. (5) MD had a similar prevalence in patients with left hemiblock and incomplete BBB (about 40% in both cases). Conclusions: MD is present in HF patients with narrow or intermediate QRS width. Selection of candidates to CRT should be based on MD, since the ECG underestimates prevalence of dyssynchrony

Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia

[ARTICOLO

Hypotensive effect of the nitrosyl ruthenium complex nitric oxide donor in renal hypertensive rats

We have described a new compound (trans-[RuCl([15]ane N(4))NO](2+)), which in vitro releases NO by the action of a reducing agent such as catecholamines. We investigated the effect of this NO donor in lowering the mean arterial pressure (MAP) in severe and moderate renal hypertensive 2K-1C rats. MAP was measured before and after intravenous in bolus injection of the compound in conscious 2K-1C and normotensive (2K) rats. In the hypertensive rats (basal 196.70 +/- 8.70 mmHg, n=5), the MAP was reduced in -34.25 +/- 13.50 mmHg(P < 0.05) 6 h after administration of 10 mmol/L/Kg of the compound in bolus. In normotensive rats the compound had no effect. We have also studied the effect of the injection of 0.1 mmol/L/Kg in normotensive (basal 118.20 +/- 11.25 mmHg, n = 4), moderate (basal 160.90 +/- 2.30 mmHg, n = 6), and severe hypertensive rats (basal 202.46 +/- 16.74 mmHg, n = 6). The compound at the dose of 0.1 mmol/L/Kg did not have effect (P> 0.05) on MAP of normotensive and moderate hypertensive rats. However, in the severe hypertensive rats (basal 202.46 +/- 16.70 mmHg, n = 6) there was a significant reduction on the MAP of -28.64 +/- 12.45 mmHg. The NO donor reduced the MAP of all hypertensive rats in the dose of 10 mmol/L/Kg and in the severe hypertensive rats at the dose of 0.1 mmol/L/Kg. The compound was not cytotoxic to the rat aortic vascular smooth muscle cells in the concentration of 0.1 mmol/LKg that produced the maximum relaxation. (C) 2008 Elsevier Inc. All rights reserved.FAPESPCNP